Tin tức & Cập nhật

High-dose PPI use among cirrhotic patients poses risk of death, complications

04 Mar 2024

Patients with cirrhosis who are exposed to high-dose proton pump inhibitors (PPIs) are at increased risk of death and cirrhotic complications, as suggested in a retrospective study.

High-dose PPI use among cirrhotic patients poses risk of death, complications

04 Mar 2024

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

04 Mar 2024 bởi

Treatment with belzutifan helps patients with previously treated advanced renal cell carcinoma (RCC) achieve better disease-specific symptoms and quality of life (QoL) compared with everolimus, according to the patient-reported outcome (PRO) data from the phase III LITESPARK-005 trial.

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

04 Mar 2024

COVID-19 vaccine–related cycle length changes linked to receipt of vaccine during follicular phase

04 Mar 2024

Receipt of the COVID-19 vaccine during the follicular phase of the menstrual cycle leads to changes in cycle length, as reported in a study.

COVID-19 vaccine–related cycle length changes linked to receipt of vaccine during follicular phase

04 Mar 2024

Subcutaneous noninferior to intravenous nivolumab for clear cell renal cell carcinoma

03 Mar 2024 bởi

Subcutaneous nivolumab is good enough for patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC) when compared with intravenous nivolumab, with no significant differences in the pharmacokinetic, efficacy, and safety endpoints, according to data from the open-label, phase III CheckMate 67T study.

Subcutaneous noninferior to intravenous nivolumab for clear cell renal cell carcinoma

03 Mar 2024

Semaglutide induces weight loss despite antidepressant use

03 Mar 2024 bởi

Treatment with semaglutide 2.4 mg results in clinically meaningful weight loss, irrespective of baseline antidepressant (AD) use, among adults with overweight/obesity, reports a post hoc study of the Semaglutide Treatment Effect for People with obesity (STEP).

Semaglutide induces weight loss despite antidepressant use

03 Mar 2024

Trastuzumab deruxtecan shows promise in metastatic breast cancer

03 Mar 2024

Treatment with trastuzumab deruxtecan (T-DXd) provides sustained antitumour activity and shows a consistent safety profile in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1), as shown by the updated survival results from the phase II DESTINY-Breast01 trial.

Trastuzumab deruxtecan shows promise in metastatic breast cancer

03 Mar 2024

Denosumab for osteoporosis shows potential for lowering diabetes risk

02 Mar 2024 bởi

Treatment with denosumab in people with osteoporosis confers a protective effect against the risk of developing diabetes, according to the results of a propensity score–matched cohort study from Taiwan.

Denosumab for osteoporosis shows potential for lowering diabetes risk

02 Mar 2024

Diazoxide choline extended-release tablet safe, effective in Prader-Willi syndrome

02 Mar 2024 bởi

Treatment with diazoxide choline extended-release tablet (DCCR) demonstrates good tolerability and delivers significant improvements in people with Prader-Willi syndrome, a rare, complex genetic neurobehavioral/metabolic disorder, results from an open-label study have shown.

Diazoxide choline extended-release tablet safe, effective in Prader-Willi syndrome

02 Mar 2024

Nivolumab + cabozantinib combo maintains survival benefit, response in advanced RCC

02 Mar 2024 bởi

The combination therapy of nivolumab plus cabozantinib (NIVO + CABO) continues to show long-term survival benefits and response rates over sunitinib at 55 months in patients with previously untreated advanced renal cell carcinoma (aRCC), according to updated results of the CheckMate 9ER study presented at ASCO GU 2024.

Nivolumab + cabozantinib combo maintains survival benefit, response in advanced RCC

02 Mar 2024

Omalizumab helps reduce allergic reactions to foods in kids

01 Mar 2024 bởi

In young children with multiple food allergies, a treatment course with omalizumab appears to increase tolerance to peanuts and other common food allergens.

Omalizumab helps reduce allergic reactions to foods in kids

01 Mar 2024

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

High-dose PPI use among cirrhotic patients poses risk of death, complications

High-dose PPI use among cirrhotic patients poses risk of death, complications

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

COVID-19 vaccine–related cycle length changes linked to receipt of vaccine during follicular phase

COVID-19 vaccine–related cycle length changes linked to receipt of vaccine during follicular phase

Subcutaneous noninferior to intravenous nivolumab for clear cell renal cell carcinoma

Subcutaneous noninferior to intravenous nivolumab for clear cell renal cell carcinoma

Semaglutide induces weight loss despite antidepressant use

Semaglutide induces weight loss despite antidepressant use

Trastuzumab deruxtecan shows promise in metastatic breast cancer

Trastuzumab deruxtecan shows promise in metastatic breast cancer

Denosumab for osteoporosis shows potential for lowering diabetes risk

Denosumab for osteoporosis shows potential for lowering diabetes risk

Diazoxide choline extended-release tablet safe, effective in Prader-Willi syndrome

Diazoxide choline extended-release tablet safe, effective in Prader-Willi syndrome

Nivolumab + cabozantinib combo maintains survival benefit, response in advanced RCC

Nivolumab + cabozantinib combo maintains survival benefit, response in advanced RCC

Omalizumab helps reduce allergic reactions to foods in kids

Omalizumab helps reduce allergic reactions to foods in kids